Legacy BioDesign


Legacy BioDesign LLC specializes in biopharmaceutical formulation and assay development, serving clients worldwide for over twenty years. The company is committed to providing high-quality support for formulation projects, with a focus on peptides, proteins, vaccines, and genetic therapies. They emphasize integrity, responsiveness, and creativity, aiming to leave a legacy of excellence and support for their clients.

Industries

biopharma
biotechnology
service-industry

Nr. of Employees

small (1-50)

Legacy BioDesign


Patents

Stable anti-OSMR antibody formulation

US-11141479-B2

View Details

Stable anti-OSMR antibody formulation

US-10493149-B2

View Details

Stable anti-OSMR antibody formulation

US-10391170-B2

View Details

Products

Books and book chapters on protein formulation

Authored and edited books and book chapters covering theory and practice of stable protein formulation, degradation pathways, and stabilization strategies.


Services

Contract research services for formulation, stabilization, assay development, and analytical characterization of biopharmaceutical products.

Development and execution of chromatography, electrophoresis, spectroscopy, calorimetry, AF4-MALLS, and dynamic imaging methods for stability and aggregate assessment.

Application of multivariate statistical tools and design of experiment strategies to interpret screening studies, optimize formulations, and analyze manufacturing data.

Educational short courses focused on peptide and protein formulation and stabilization.

A subscription offering intended to keep clients informed on developments relevant to formulation and assay development.

Expertise Areas

  • Protein and peptide formulation
  • Developability assessment and candidate selection
  • Analytical method development and orthogonal characterization
  • Aggregate and subvisible particle characterization
  • Show More (6)

Key Technologies

  • High-performance liquid chromatography (HPLC/UHPLC)
  • Size-exclusion chromatography (SEC)
  • Reversed-phase, ion-exchange, hydrophobic interaction chromatography
  • Asymmetrical flow field-flow fractionation (AF4)
  • Show More (12)

News & Updates

Celebrating 20 years of service in May 2024, with clients in nearly 20 countries and several drugs in late-stage trials or marketed.

A highly cited review article published in 2010, recognized as a Highly Cited Article by Web of Science.

Scientists at Legacy have been named as inventors on over 50 US patents related to formulation and biopharmaceuticals.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.